FDA Approves Gilead's Long-Acting HIV Prevention Injection
TL;DR
The FDA has approved Gilead Sciences' twice-yearly injection, lenacapavir, for HIV prevention, showing over 99.9% effectiveness in clinical trials, which could be a major breakthrough in HIV prevention efforts, though concerns about high costs remain.
- Breakthrough: FDA Approves Injection to Prevent HIV ScienceAlert
- Regulators Approve Lenacapavir for H.I.V. Prevention The New York Times
- Gilead’s CEO on the approval of a powerful new drug to prevent HIV STAT
- HIV prevention drug hailed as a 'breakthrough' gets FDA approval : Goats and Soda NPR
- US FDA approves Gilead's twice-yearly injection for HIV prevention Reuters
Want the full story? Read the original reporting
Read on ScienceAlert